

OBI-833 was safe and immunogenic, without treatmentrelated SAE, in a Phase 1 doseescalation trial

Her-Shyong Shiah MD

Assistant Professor, Taipei Tzu Chi Hospital





I have no conflict of interests to declare.

The study was sponsored by OBI Pharma.

URITAL ESMOASIA OBI-833 Active Immunotherapy

A Novel Cancer Vaccine Targeting Globo H

Globo H, a unique hexasaccharide, is expressed on multiple epithelial cancers and leading to poor outcome.





Dose Escalation Study Design and Baseline Characteristics of Enrolled Subjects





Safety was Primarily Related to Injection Site Reactions

	Treatment Related AE		Non-Treatment Related AE	
	Total AE	111	Total AE	72
	Grade 2 Grade 1	15 (1 subject)	Grade 5 Grade 4	2
		6 Swelling at injection site 9 Soreness at injection site		acute respiratory failure* death due to disease progression*
		06 (11 subjects)		2
		90 (TT Subjects)		hyponatremia*
		swelling at injection site, fever, macular rash on bilateral legs, erythema at injection site, burning sensation at injection site, pruritus at injection site, tenderness at injection site, induration at injection site, tingling at injection site, joint pain, anemia, insomnia, flu-like syndrome	Grade 3	5
				hyperbilirubinemia, chest wall pain, worsening dyspnea, malignant bilateral pleural effusions* and hypertension
			Grade 2	23
				urinary tract infection, dehydration, anorexia, back pain, nausea, weight loss, coronary artery disease, anemia, and acute kidney injury*
*There were five non-treatment related SAEs reported: Acute respiratory failure due to pneumonia (CRC with lung metastasis) at visit 4 leading to death in Cohort 1; Death due to disease progression (CRC) after discontinuation of treatment at visit 5;			Grade 1	40
				hypertension, anorexia, weight loss, peripheral edema, cough, intermittent cough, and dysgeusia, epistaxis, right rib cage pain and gallstone
CRC	CRC subject with renal insufficiency developed Grade 4 hyponatremia and			
Grad	Grade 2 Acute Kidney Injury in Cohort 3 (visit 9);			
Grade 3 malignant dilateral pleural ettusion associated with disease				

progression (CRC with lung and liver metastasis) at visit 4 in Cohort 3;

Anti-Globo H IgM are Associated with Tumor-targeting Complement-dependent Cytotoxicity (CDC) Activity



All three doses of OBI-833/OBI-821 elicited anti-Globo H IgM antibody response

VIRTUAL

- Robust anti-Globo H IgM response was induced in subject 001-001 (lung cancer)
- Anti-Globo H IgM are associated with CDC tumor killing activities in a dose-dependent manner





51

ADCC | 0.5

50

Anti-Globo H IgG (µg/ml)

100

Levels of anti-Globo H IgG do not correlate with ADCC tumor killing activities.

41

31

Weeks

40

20

▲ Injection



- OBI-833 was well tolerated, with only grade 1-2 treatment-related injection site reactions.
- All immunized patients induced good IgM responses against Globo H, confirming its immunogenicity. One patient with NSCLC had a robust anti-Globo H IgG response.
- Additional Cohort Expansion Study results in patients with NSCLC will be presented in poster section.



I thank

- Patients and their families
- All OBI-833 investigators
- OBI Pharma medical team





Thanks for Your Attention!

